Prevalence and factors associated with dry skin in HIV infection: The FRAM study

AIDS

Volumn 21, Issue 15, 2007, Pages 2051-2057

  Lee, Daniel ^a   Benson, Constance A ^a   Lewis, Cora E ^b   Grunfeld, Carl ^c,d,e   Scherzer, Rebecca ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complication; Dermatology; Opportunistic infection; Protease inhibitors; Retinoid

Indexed keywords

COCAINE; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACNE; ADULT; ARTICLE; ATOPY; CD4+ T LYMPHOCYTE; CLINICAL EXAMINATION; CLINICAL STUDY; CONTROL GROUP; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRY SKIN; FEMALE; FOOD INTAKE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OPPORTUNISTIC INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SKIN DISEASES; UNITED STATES;

EID: 34648840098     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282eea51a     Document Type: Article

References (25)

1. Costner M, Cockerell CJ. The changing spectrum of the cutaneous manifestations of HIV disease. Arch Dermatol 1998; 134:1290-1292.
2. Spira R, Mignard M, Doutre MS, Morlat P, Dabis F. Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Arch Dermatol 1998; 134:1208-1212.
3. Goodman DS, Teplitz ED, Wishner A, Klein RS, Burk PG, Hershenbaum E. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. J Am Acad Dermatol 1987; 17:210-220.
4. Munoz-Perez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol 1998; 139:33-39.
5. Rowe A, Mallon E, Rosenberger P, Barrett M, Walsh J, Bunker CB. Depletion of cutaneous peptidergic innervation in HIV-associated xerosis. J Invest Dermatol 1999; 112:284-289.
6. Hengge UR, Franz B, Goos M. Decline of infectious skin manifestations in the era of highly active antiretroviral therapy. AIDS 2000; 14:1069-1070.
7. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860-869.
8. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116.
9. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
10. Garcia-Silva J, Almagro M, Juega J, Pena C, Lopez-Calvo S, del Pozo J, et al. Protease inhibitor-related paronychia, ingrown toenails, desquamative cheilitis and cutaneous xerosis. AIDS 2000; 14:1289-1291.
11. Bouscarat F, Bouchard C, Bouhour D. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 1998; 338:1776-1777.
12. Alam M, Scher RK. Indinavir-related recurrent paronychia and ingrown toenails. Cutis 1999; 64:277-278.
13. Calista D, Boschini A. Cutaneous side effects induced by indinavir. Eur J Dermatol 2000; 10:292-296.
14. Sass JO, Jakob-Solder B, Heitger A, Tzimas G, Sarcletti M. Paronychia with pyogenic granuloma in a child treated with indinavir: the retinoid-mediated side effect theory revisited. Dermatology (Basel, Switzerland) 2000; 200:40-42.
15. Garcia-Silva J, Almagro M, Pena-Penabad C, Fonseca E. Indinavir-induced retinoid-like effects: incidence, clinical features and management. Drug Safety 2002; 25:993-1003.
16. Garman ME, Tyring SK. The cutaneous manifestations of HIV infection. Dermatol Clin 2002; 20:193-208.
17. Terheggen F, Frissen J, Weigel H, Schouten I, Brinkman K. Nail, hair and skin hyperpigmentation associated with indinavir therapy. AIDS 2004; 18:1612.
18. Lenhard JM, Weiel JE, Paulik MA, Furfine ES. Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. Biochem Pharmacol 2000; 59:1063-1068.
19. Ikezoe T, Daar ES, Hisatake J, Taguchi H, Koeffler HP. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 2000; 96:3553-3559.
20. Toma E, Devost D, Chow Lan N, Bhat PV. HIV-protease inhibitors alter retinoic acid synthesis. AIDS 2001; 15:1979-1984.
21. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98:79-85.
22. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
23. Kaplan MH, Sadick N, McNutt NS, Meltzer M, Sarngadharan MG, Pahwa S. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1987; 16:485-506.
24. Uthayakumar S, Nandwani R, Drinkwater T, Nayagam AT, Darley CR. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 1997; 137:595-598.
25. Hediger C, Rost B, Itin P. Cutaneous manifestations in anorexia nervosa. Schweiz Med Wochenschr 2000; 130:565-575.